Evidence for link between ‘leaky gut’ and autoantibody production in HIV-positive patients

Human immunodeficiency virus, or HIV, attacks the immune system, making individuals more susceptible to infections. When patients with HIV are treated with antiretroviral therapy (ART), their immune system can recover. However, some of them produce self-destructive proteins, or autoantibodies.

Instead of attacking foreign invaders such as bacteria or viruses, some autoantibodies attack the body’s own cells. This is known as autoimmunity.

We all produce low levels of autoantibodies. But when they are produced persistently at high levels, autoimmunity can occur.

Wei Jiang, M.D., associate professor in the Department of Microbiology and Immunology at the Medical University of South Carolina (MUSC), and her team found that HIV-positive, ART-treated patients with high levels of autoantibodies also have increased levels of bacteria (staphylococcus aureus) products in their blood. Their findings were published online February 14, 2019 by Microbiome.

“We are now studying which staphylococcus products are active in autoantibody production in mice. It may be possible to design an inhibitor to block these bacteria from activating the immune cells.” -- Dr. Wei Jiang

The MUSC study compared autoantibody production in HIV-positive patients and healthy individuals before and after receiving a seasonal flu vaccine. Patients provided blood samples before vaccination and one and two weeks after. The blood samples were tested using a 125-autoantibody array panel.

The autoimmune response in the HIV-positive patients was linked to the presence of staphylococcus aureus products in the blood. This is the same bacteria responsible for skin staph infections.  Some HIV-positive patients have a higher baseline level of these bacterial products in their system.

The team examined other strains of bacteria but linked only staphylococcus aureus to autoantibody production in HIV-positive individuals.

A “leaky gut” could explain the increased level of staphylococcus products in the blood of HIV-positive patients. In patients with “leaky gut,” the intestinal lining is weakened. This enables bacteria and toxic products in the  gut to enter the bloodstream, where they become vulnerable to the immune system.

The immune system’s attacks on these bacteria could also injure the body’s own tissues. A “leaky gut” is associated with persistent inflammation and several chronic illnesses. These include HIV, irritable bowel syndrome, celiac disease, and type 1 diabetes.

To verify their findings, Jiang and her team injected heat-killed staphylococcus bacteria into healthy mice. They found that doing so did in fact stimulate autoantibody production.

“We used animals to verify what we found in humans,” explains Jiang. “We saw that the level of staphylococcus product was correlated with autoantibody production in HIV patients, and we hypothesized that these bacteria induced autoantibodies, so we tested our hypothesis in mice.”

The ability to further explore clinical findings in an animal model was crucial to this study. The mouse study showed that injection of staphylococcus bacteria stimulates autoantibody production.

The mouse studies were supported by voucher funding from the South Carolina Clinical & Translational Research (SCTR) Institute, an NIH-funded Clinical and Translational Science Awards hub at MUSC.

“We are now studying which staphylococcus products are active in autoantibody production in mice,” says Jiang. “It may be possible to design an inhibitor to block these bacteria from activating the immune cells.”

Going forward, Jiang and her team hope to design a drug that inhibits staphylococcus to help prevent autoimmunity in HIV-positive patients receiving ART.